March 28, 2016 8:30am EDT
Download as PDF
Ronald Trust, Ph.D., MBA, Appointed Vice President of Regulatory
Affairs
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK )
today announced the appointment of Dr. Ronald Trust as Vice President of
Regulatory Affairs of OPKO Pharmaceuticals.
Prior to joining OPKO, Ron held senior regulatory positions at Allergan
(through its acquisition of Durata Therapeutics), spent over 16 years at
Pfizer in various regulatory affairs positions, and most recently worked
as an independent consultant providing strategic regulatory consulting
services to the pharmaceutical industry. Ron received his PhD in organic
chemistry from the California Institute of Technology and he also holds
a Masters in Business Administration from Fairleigh Dickinson University.
“Ron has over 40 years of pharmaceutical industry development
experience, including over 30 years in regulatory affairs, safety/risk
management and quality assurance, which will be of tremendous value as
we continue to bring our product candidates to market,” said Phillip
Frost, M.D., Chairman and Chief Executive Officer of OPKO.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched by
partner Tesaro, IV formulation in Phase 3). Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in Phase
3 and partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia (in Phase 2a). We also have production and distribution
assets worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com .
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including all non-historical statements about our expectations,
beliefs or intentions regarding our business, technologies and products,
financial condition, strategies, prospects, growth opportunities, and
management. Many factors could cause our actual activities or results to
differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in our
filings with the Securities and Exchange Commission, and risks inherent
in funding, developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments. In
addition, forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and, except as
required by applicable law, we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005365/en/
OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor
Relations
or
Media
Rooney & Associates
Terry
Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released March 28, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page